ERCC1-Specific Immunostaining in Non–Small-Cell Lung Cancer
Authors:
- Ken A. OlaussenKOKen A. Olaussen
- Pierre FouretPFPierre Fouret
- Guido KroemerGuido Kroemer
- 11 October 2007
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (15) , 1559-1561
Abstract
In their letter to the editor, Niedernhofer et al. (June 14 issue)1 have doubts about the specificity of the monoclonal mouse antibody 8F1, which is used to detect the excision repair cross-complementation group 1 (ERCC1) protein. These doubts are important to reconcile, because two studies have reported that high levels of ERCC1 expression, as detected by means of immunohistochemical staining of primary tumors with the use of the 8F1 monoclonal antibody, are associated with a good prognosis in non–small-cell lung cancer yet negatively affect the response to chemotherapeutic agents.2,3 Hence, the expression level of the epitope recognized by 8F1 (presumably ERCC1) may influence the management of non–small-cell lung cancer.Keywords
This publication has 5 references indexed in Scilit:
- ERCC1 and Non–Small-Cell Lung CancerNew England Journal of Medicine, 2007
- DNA Synthesis and Repair GenesRRM1andERCC1in Lung CancerNew England Journal of Medicine, 2007
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatinBiochemical and Biophysical Research Communications, 2005
- Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cellsDNA Repair, 2004